AI Score
Our AI model analyzes fundamental, technical, and statistical indicators
to predict the probability of a bullish trend over the next three months.
We regularly update and refine our models to deliver the most reliable forecasts
for you.
Bullish Probability | Sentiment | Score |
---|---|---|
+80% | Strong Buy | 10 |
+75% | Buy | 9 |
+70% | Buy | 8 |
+60% | Buy | 7 |
+50% | Hold | 6 |
+45% | Hold | 5 |
+40% | Hold | 4 |
+35% | Sell | 3 |
+30% | Sell | 2 |
+20% | Strong Sell | 1 |
Hepion Pharmaceuticals Statistics
Share Statistics
Hepion Pharmaceuticals has 6.96M shares outstanding. The number of shares has increased by 60.42% in one year.
Shares Outstanding | 6.96M |
Shares Change (YoY) | n/a |
Shares Change (QoQ) | 19.99% |
Owned by Institutions (%) | n/a |
Shares Floating | 6.95M |
Failed to Deliver (FTD) Shares | 122 |
FTD / Avg. Volume | 0.2% |
Short Selling Information
The latest short interest is 65.73K, so 0.94% of the outstanding shares have been sold short.
Short Interest | 65.73K |
Short % of Shares Out | 0.94% |
Short % of Float | 0.95% |
Short Ratio (days to cover) | 0.92 |
Valuation Ratios
The PE ratio is -0.26 and the forward PE ratio is -0.05.
PE Ratio | -0.26 |
Forward PE | -0.05 |
PS Ratio | 0 |
Forward PS | null |
PB Ratio | 1.77 |
P/FCF Ratio | -0.31 |
PEG Ratio | n/a |
Enterprise Valuation
Currently the Enterprise Value (EV) is not available for Hepion Pharmaceuticals Inc..
EV / Earnings | n/a |
EV / Sales | n/a |
EV / EBITDA | n/a |
EV / EBIT | n/a |
EV / FCF | n/a |
Financial Position
The company has a current ratio of 3.31, with a Debt / Equity ratio of 0.
Current Ratio | 3.31 |
Quick Ratio | 3.31 |
Debt / Equity | 0 |
Total Debt / Capitalization | 0 |
Cash Flow / Debt | 0 |
Interest Coverage | -5118.64 |
Financial Efficiency
Return on equity (ROE) is -6.72% and return on capital (ROIC) is -641.49%.
Return on Equity (ROE) | -6.72% |
Return on Assets (ROA) | -2.7% |
Return on Capital (ROIC) | -641.49% |
Revenue Per Employee | 0 |
Profits Per Employee | -2.22M |
Employee Count | 22 |
Asset Turnover | 0 |
Inventory Turnover | 0 |
Taxes
Income Tax | -409.02K |
Effective Tax Rate | 0.01 |
Stock Price Statistics
The stock price has increased by -81.25% in the last 52 weeks. The beta is 1.81, so Hepion Pharmaceuticals 's price volatility has been higher than the market average.
Beta | 1.81 |
52-Week Price Change | -81.25% |
50-Day Moving Average | 0.6 |
200-Day Moving Average | 0.95 |
Relative Strength Index (RSI) | 40.94 |
Average Volume (20 Days) | 59.76K |
Income Statement
Revenue | n/a |
Gross Profit | -67.13K |
Operating Income | -48.45M |
Net Income | -48.93M |
EBITDA | -49.26M |
EBIT | n/a |
Earnings Per Share (EPS) | -12.32 |
Balance Sheet
The company has 14.79M in cash and 209.02K in debt, giving a net cash position of 14.58M.
Cash & Cash Equivalents | 14.79M |
Total Debt | 209.02K |
Net Cash | 14.58M |
Retained Earnings | -224.63M |
Total Assets | 3.72M |
Working Capital | 814.33K |
Cash Flow
In the last 12 months, operating cash flow was -40.89M and capital expenditures -14.30K, giving a free cash flow of -40.90M.
Operating Cash Flow | -40.89M |
Capital Expenditures | -14.30K |
Free Cash Flow | -40.90M |
FCF Per Share | -10.3 |
Margins
Gross Margin | n/a |
Operating Margin | n/a |
Pretax Margin | n/a |
Profit Margin | n/a |
EBITDA Margin | n/a |
EBIT Margin | n/a |
FCF Margin | n/a |
Dividends & Yields
HEPA does not appear to pay any dividends at this time.
Dividend Per Share | n/a |
Dividend Yield | n/a |
Dividend Growth (YoY) | n/a |
Payout Ratio | n/a |
Earnings Yield | -2566.67% |
FCF Yield | -1224.64% |
Analyst Forecast
Currently there are no analyst rating for HEPA.
Price Target | n/a |
Price Target Difference | n/a |
Analyst Consensus | n/a |
Analyst Count | n/a |
Stock Splits
The last stock split was on May 11, 2023. It was a backward split with a ratio of 1:20.
Last Split Date | May 11, 2023 |
Split Type | backward |
Split Ratio | 1:20 |
Scores
Altman Z-Score | -114.92 |
Piotroski F-Score | 1 |